By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Antidiabetic combinations > Juvisync > Simvastatin / Sitagliptin Dosage
Antidiabetic combinations
https://themeditary.com/dosage-information/simvastatin-sitagliptin-dosage-3000.html

Simvastatin / Sitagliptin Dosage

Drug Detail:Juvisync (Simvastatin and sitagliptin [ sim-va-stat-in-and-sit-a-glip-tin ])

Drug Class: Antidiabetic combinations Antihyperlipidemic combinations

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Diabetes Type 2

Initial dose: Simvastatin 40 mg-sitagliptin 100 mg orally once a day in the evening
Maintenance dose: Simvastatin 10 to 50 mg-sitagliptin 50 to 100 mg orally once a day in the evening

  • For patients already taking simvastatin with or without sitagliptin: Initiate at the dose of simvastatin already being taken and sitagliptin at 100 mg orally daily.

  • For patients taking verapamil, diltiazem, or dronedarone: Simvastatin 10 mg-sitagliptin 50 or 100 mg orally daily. Dose of simvastatin should not exceed 10 mg per day.

  • For patients taking amiodarone, amlodipine or ranolazine: Simvastatin 20 mg-sitagliptin 50 or 100 mg orally daily. Dose of simvastatin should not exceed 20 mg per day.

  • Patients with Homozygous Familial Hypercholesterolemia: Simvastatin 40 mg-sitagliptin 100 mg orally daily.

  • Concomitant use with lomitapide: Simvastatin 20 mg-sitagliptin 100 mg orally daily.

  • Chinese patients taking Lipid-Modifying doses (greater than or equal to 1 g per day of Niacin): Simvastatin 40 mg-sitagliptin 50 to 100 mg should be used with caution.

Comments: If this drug is used in combination with an insulin secretagogue or with insulin, a lower dose of insulin or insulin secretagogue may be required to reduce risk of hypoglycemia.

Uses: Simvastatin: Reduce risk of non-fatal myocardial infarction, stroke, and the need for revascularization in patients at high risk of coronary events. Reduce elevated total cholesterol, LDL, TG, VLDL and increase HDL in patients with primary hyperlipidemia (Heterozygous Familial and Nonfamilial) and mixed dyslipidemia. Reduce elevated TG in patients with hypertriglyceridemia and reduce TG and VLDL-C in patients with primary dysbetalipoproteinemia. Reduce total cholesterol in patients with homozygous familial hypercholesterolemia. Sitagliptin: Adjunct therapy to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Usual Adult Dose for Hyperlipidemia

Initial dose: Simvastatin 40 mg-sitagliptin 100 mg orally once a day in the evening
Maintenance dose: Simvastatin 10 to 50 mg-sitagliptin 50 to 100 mg orally once a day in the evening

  • For patients already taking simvastatin with or without sitagliptin: Initiate at the dose of simvastatin already being taken and sitagliptin at 100 mg orally daily.

  • For patients taking verapamil, diltiazem, or dronedarone: Simvastatin 10 mg-sitagliptin 50 or 100 mg orally daily. Dose of simvastatin should not exceed 10 mg per day.

  • For patients taking amiodarone, amlodipine or ranolazine: Simvastatin 20 mg-sitagliptin 50 or 100 mg orally daily. Dose of simvastatin should not exceed 20 mg per day.

  • Patients with Homozygous Familial Hypercholesterolemia: Simvastatin 40 mg-sitagliptin 100 mg orally daily.

  • Concomitant use with lomitapide: Simvastatin 20 mg-sitagliptin 100 mg orally daily.

  • Chinese patients taking Lipid-Modifying doses (greater than or equal to 1 g per day of Niacin): Simvastatin 40 mg-sitagliptin 50 to 100 mg should be used with caution.

Comments: If this drug is used in combination with an insulin secretagogue or with insulin, a lower dose of insulin or insulin secretagogue may be required to reduce risk of hypoglycemia.

Uses: Simvastatin: Reduce risk of non-fatal myocardial infarction, stroke, and the need for revascularization in patients at high risk of coronary events. Reduce elevated total cholesterol, LDL, TG, VLDL and increase HDL in patients with primary hyperlipidemia (Heterozygous Familial and Nonfamilial) and mixed dyslipidemia. Reduce elevated TG in patients with hypertriglyceridemia and reduce TG and VLDL-C in patients with primary dysbetalipoproteinemia. Reduce total cholesterol in patients with homozygous familial hypercholesterolemia. Sitagliptin: Adjunct therapy to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Usual Adult Dose for Homozygous Familial Hypercholesterolemia

Initial dose: Simvastatin 40 mg-sitagliptin 100 mg orally once a day in the evening
Maintenance dose: Simvastatin 10 to 50 mg-sitagliptin 50 to 100 mg orally once a day in the evening

  • For patients already taking simvastatin with or without sitagliptin: Initiate at the dose of simvastatin already being taken and sitagliptin at 100 mg orally daily.

  • For patients taking verapamil, diltiazem, or dronedarone: Simvastatin 10 mg-sitagliptin 50 or 100 mg orally daily. Dose of simvastatin should not exceed 10 mg per day.

  • For patients taking amiodarone, amlodipine or ranolazine: Simvastatin 20 mg-sitagliptin 50 or 100 mg orally daily. Dose of simvastatin should not exceed 20 mg per day.

  • Patients with Homozygous Familial Hypercholesterolemia: Simvastatin 40 mg-sitagliptin 100 mg orally daily.

  • Concomitant use with lomitapide: Simvastatin 20 mg-sitagliptin 100 mg orally daily.

  • Chinese patients taking Lipid-Modifying doses (greater than or equal to 1 g per day of Niacin): Simvastatin 40 mg-sitagliptin 50 to 100 mg should be used with caution.

Comments: If this drug is used in combination with an insulin secretagogue or with insulin, a lower dose of insulin or insulin secretagogue may be required to reduce risk of hypoglycemia.

Uses: Simvastatin: Reduce risk of non-fatal myocardial infarction, stroke, and the need for revascularization in patients at high risk of coronary events. Reduce elevated total cholesterol, LDL, TG, VLDL and increase HDL in patients with primary hyperlipidemia (Heterozygous Familial and Nonfamilial) and mixed dyslipidemia. Reduce elevated TG in patients with hypertriglyceridemia and reduce TG and VLDL-C in patients with primary dysbetalipoproteinemia. Reduce total cholesterol in patients with homozygous familial hypercholesterolemia. Sitagliptin: Adjunct therapy to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Usual Adult Dose for Heterozygous Familial Hypercholesterolemia

Initial dose: Simvastatin 40 mg-sitagliptin 100 mg orally once a day in the evening
Maintenance dose: Simvastatin 10 to 50 mg-sitagliptin 50 to 100 mg orally once a day in the evening

  • For patients already taking simvastatin with or without sitagliptin: Initiate at the dose of simvastatin already being taken and sitagliptin at 100 mg orally daily.

  • For patients taking verapamil, diltiazem, or dronedarone: Simvastatin 10 mg-sitagliptin 50 or 100 mg orally daily. Dose of simvastatin should not exceed 10 mg per day.

  • For patients taking amiodarone, amlodipine or ranolazine: Simvastatin 20 mg-sitagliptin 50 or 100 mg orally daily. Dose of simvastatin should not exceed 20 mg per day.

  • Patients with Homozygous Familial Hypercholesterolemia: Simvastatin 40 mg-sitagliptin 100 mg orally daily.

  • Concomitant use with lomitapide: Simvastatin 20 mg-sitagliptin 100 mg orally daily.

  • Chinese patients taking Lipid-Modifying doses (greater than or equal to 1 g per day of Niacin): Simvastatin 40 mg-sitagliptin 50 to 100 mg should be used with caution.

Comments: If this drug is used in combination with an insulin secretagogue or with insulin, a lower dose of insulin or insulin secretagogue may be required to reduce risk of hypoglycemia.

Uses: Simvastatin: Reduce risk of non-fatal myocardial infarction, stroke, and the need for revascularization in patients at high risk of coronary events. Reduce elevated total cholesterol, LDL, TG, VLDL and increase HDL in patients with primary hyperlipidemia (Heterozygous Familial and Nonfamilial) and mixed dyslipidemia. Reduce elevated TG in patients with hypertriglyceridemia and reduce TG and VLDL-C in patients with primary dysbetalipoproteinemia. Reduce total cholesterol in patients with homozygous familial hypercholesterolemia. Sitagliptin: Adjunct therapy to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Usual Adult Dose for Cardiovascular Risk Reduction

Initial dose: Simvastatin 40 mg-sitagliptin 100 mg orally once a day in the evening
Maintenance dose: Simvastatin 10 to 50 mg-sitagliptin 50 to 100 mg orally once a day in the evening

  • For patients already taking simvastatin with or without sitagliptin: Initiate at the dose of simvastatin already being taken and sitagliptin at 100 mg orally daily.

  • For patients taking verapamil, diltiazem, or dronedarone: Simvastatin 10 mg-sitagliptin 50 or 100 mg orally daily. Dose of simvastatin should not exceed 10 mg per day.

  • For patients taking amiodarone, amlodipine or ranolazine: Simvastatin 20 mg-sitagliptin 50 or 100 mg orally daily. Dose of simvastatin should not exceed 20 mg per day.

  • Patients with Homozygous Familial Hypercholesterolemia: Simvastatin 40 mg-sitagliptin 100 mg orally daily.

  • Concomitant use with lomitapide: Simvastatin 20 mg-sitagliptin 100 mg orally daily.

  • Chinese patients taking Lipid-Modifying doses (greater than or equal to 1 g per day of Niacin): Simvastatin 40 mg-sitagliptin 50 to 100 mg should be used with caution.

Comments: If this drug is used in combination with an insulin secretagogue or with insulin, a lower dose of insulin or insulin secretagogue may be required to reduce risk of hypoglycemia.

Uses: Simvastatin: Reduce risk of non-fatal myocardial infarction, stroke, and the need for revascularization in patients at high risk of coronary events. Reduce elevated total cholesterol, LDL, TG, VLDL and increase HDL in patients with primary hyperlipidemia (Heterozygous Familial and Nonfamilial) and mixed dyslipidemia. Reduce elevated TG in patients with hypertriglyceridemia and reduce TG and VLDL-C in patients with primary dysbetalipoproteinemia. Reduce total cholesterol in patients with homozygous familial hypercholesterolemia. Sitagliptin: Adjunct therapy to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Renal Dose Adjustments

Severe renal dysfunction (CrCl less than 30 mL/min): Appropriate doses are not available and therefore use is not recommended
Moderate renal dysfunction (CrCl 30 to less than 50 mL/min): Initial dose: simvastatin 40 mg-sitagliptin 50 mg orally once a day; for patients already taking simvastatin with or without sitagliptin 50 mg daily, the initial dose should be the dose of simvastatin already being taken and sitagliptin 50 mg.
Mild renal dysfunction (CrCl greater than 50 mL/min): No adjustment recommended.

Patients with Homozygous Familial Hypercholesterolemia:

  • Severe renal dysfunction (CrCl less than 30 mL/min): Appropriate doses are not available and therefore use is not recommended
  • Moderate renal dysfunction (CrCl 30 to less than 50 mL/min): Simvastatin 40 mg-sitagliptin 50 mg orally once a day in the evening.
  • Mild renal dysfunction (CrCl greater than 50 mL/min): Simvastatin 40 mg-sitagliptin 100 mg orally daily.
Comments: Simvastatin-sitagliptin should be used as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) in these patients or if such treatments are unavailable.

Concomitant use with lomitapide:
  • Severe renal dysfunction (CrCl less than 30 mL/min): Not recommended
  • Moderate renal dysfunction (CrCl 30 to less than 50 mL/min): Maximum dose should not exceed simvastatin 20 mg-sitagliptin 50 mg orally daily. If a patient had previously taken simvastatin 80 mg daily chronically (e.g., for 12 months or more) without evidence of muscle toxicity, the maximum dose should not exceed simvastatin 40 mg-sitagliptin 50 orally daily.
  • Mild renal dysfunction (CrCl greater than 50 mL/min): Maximum dose should not exceed simvastatin 20 mg-sitagliptin 100 mg orally daily. If a patient had previously taken simvastatin 80 mg daily chronically (e.g., for 12 months or more) without evidence of muscle toxicity, the maximum dose should not exceed simvastatin 40 mg-sitagliptin 100 orally daily.

Liver Dose Adjustments

Contraindicated

Dose Adjustments

After initiation or titration of this drug, lipid levels may be analyzed after 4 or more weeks and dose adjusted, if needed.

Precautions

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • Tablets must never be split before swallowing.
  • Tablets can be taken with or without food, although co-administration with high-fat meals is not recommended.

Monitoring:
  • Metabolic: Blood glucose (A1C) levels
  • Hepatic: Transaminases and cholesterol levels

Patient advice:
  • Diet, a regular exercise program and periodic testing of fasting lipid panel is recommended.
  • Inform other healthcare professionals prescribing a new medication or increasing the dose of existing medication that you are taking simvastatin-sitagliptin.
  • Measurement of A1C is especially useful for evaluating long-term glycemic control.
  • There is a potential need to adjust the dose or discontinue this drug based on changes of renal function over time.
  • Report promptly any symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine, jaundice, unexplained muscle pain, tenderness or weakness particularly if accompanied by malaise or fever or if these muscle signs persist after discontinuing simvastatin-sitagliptin.
  • Instruct patients to contact their health care provider if they develop severe and persistent joint pain
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by